



Peter Sinn

Kontakt

Peter Sinn

Publikationen (5)

Banys-Paluchowski M, Thill M, Kühn T, Ditsch N, Heil J, Wöckel A, Fallenberg E, Friedrich M, Kümmel S, Müller V, Janni W, Albert U, Bauerfeind I, Blohmer J, Budach W, Dall P, Fasching P, Fehm T, Gluz O, Harbeck N, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe H, Krug D, Loibl S, Luftner D, Lux M, Maass N, Mundhenke C, Nitz U, Park-Simon T, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn P, Solbach C, Solomayer E, Stickeler E, Thomssen C, Untch M, Witzel I, Gerber B. AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022. *Geburtshilfe Frauenheilkd* 2022; 82:1031-1043.

Villegas S, Huober J, Lederer B, van Mackelenbergh M, Tesch H, Jackisch C, Rezai M, Sinn P, Sinn B, Hackmann J, Kiechle M, Schneeweiss A, Weichert W, Denkert C, Schmitt W, Hanusch C, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, Holms F, Ulmer H, Fasching P, Weber K, Albig C, Heinrichs C, Marme F, Hartmann A, Loibl S. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. *Eur J Cancer* 2021; 148:159-170.

Denkert C, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching P, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Kümmel S, Pfitzner B, Karn T, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner B, Weber K, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt W, Blohmer J, Loibl S. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. *Lancet Oncol* 2017; 19:40-50.

Untch M, Luftner D, Möbus V, Müller V, Rody A, Sinn P, Thill M, Thomssen C, Harbeck N, Kühn T, Janni W, Gerber B, Huober J, Jackisch C, Schneeweiss A, Brucker S, Dall P, Denkert C, Fasching P, Fehm T, Liedtke C. Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). *Geburtshilfe Frauenheilkd* 2017; 77:633-644.

Loibl S, Fasching P, Andre F, Lindner J, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Pfitzner B, Huober J, Heinrichs C, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm D, Sinn P, Khandan F, Eidtmann H, Dohnal K, Denkert C. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. *J Clin Oncol* 2014; 32:3212-20.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch